Moody Aldrich Partners’s AnaptysBio ANAB Stock Holding History

Moody Aldrich Partners’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.09M	Sell	30,926 -8,529	-22%	-$517K	0.38%	105
2026 Q1	$2.19M	Sell	39,455 -8,146	-17%	-$438K	0.39%	105
2025 Q4	$2.31M	Sell	47,601 -2,281	-5%	-$88.9K	0.43%	101
2025 Q3	$1.53M	Sell	49,882 -10,212	-17%	-$234K	0.29%	109
2025 Q2	$1.33M	Sell	60,094 -23,130	-28%	-$484K	0.26%	106
2025 Q1	$1.55M	Buy	+83,224	New	+$1.39M	0.32%	101
2018 Q1	–	Sell	-9,290	Closed	-$936K	–	90
2017 Q4	$936K	Buy	+9,290	New	+$684K	0.76%	69

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Moody Aldrich Partners's ANAB Position: Q2 2026 in Review

Moody Aldrich Partners reduced its AnaptysBio (ANAB) stake by 22% in Q2 2026, selling an estimated $517K and leaving 30,926 shares worth $2.09M. The position accounts for 0.38% of the portfolio, ranked #105.

Moody Aldrich Partners first reported a position in ANAB in Q4 2017 and has held it in 7 quarters since. The position peaked at $2.31M in Q4 2025. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Moody Aldrich Partners held 30,926 shares of AnaptysBio worth $2.09M as of Q2 2026.
Moody Aldrich Partners sold 8,529 AnaptysBio shares in Q2 2026, an estimated $517K.
AnaptysBio made up 0.38% of Moody Aldrich Partners's portfolio in Q2 2026, its #105 holding.
Moody Aldrich Partners first reported a position in AnaptysBio in Q4 2017 and has held it in 7 quarters since.
Moody Aldrich Partners's AnaptysBio position peaked at $2.31M in Q4 2025.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.